Featured Cancer Clinical Trials

Learn about featured cancer clinical trials currently enrolling, or search our cancer clinical trials database for all open and accruing studies.

Myeloproliferative Neoplasms
A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Luspatercept (ACE-536) in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia With and Without Red Blood Cell-Transfusion Dependence
CLGN 1917
View full trial information

Advertising Policy

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy

Myelodysplastic Syndrome (MDS)
A Phase 1 Study to Evaluate the Safety and Tolerability of MEDI4736 as Monotherapy or in Combination with Tremelimumab with or without Azacitidine in Subjects with Myelodysplastic Syndrome after Treatment with Hypomethylating Agents
MEDI 1917
View full trial information

Essential Thrombocythemia, Myelofibrosis
Prospective, longitudinal, non-interventional study of disease burden and treatment of patients with low-risk myelofibrosis (mf) or high-risk essential thrombocythemia (ET) or et patients receiving et-directed therapy
View full trial information

Lymphoma, Diffuse Large B Cell, Lymphoma, Non – Hodgkin
A Phase 2 Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination with Rituximab in Patients with Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma and Other Forms of Non-Hodgkin’s Lymphoma
DBPI 1415
View full trial information

Advertising Policy

Leukemia, Acute Myeloid (AML), Leukemia, Chronic Myelomonocytic (CMML), Myelodysplastic Syndrome (MDS)
An Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia
H3BM 1916
View full trial information

Search our Cancer Clinical Trials Database for a full listing of all open and accruing studies.